The oral RNA-splicing modifier lowered mutant huntingtin and PMS1, but its clinical signal came from a small externally controlled analysis
Key Takeaways
- SKY-0515 showed a 1.59-point cUHDRS advantage over a weighted external control at Month 15.
- At 9 mg, average mutant huntingtin reduction exceeded 60%, while PMS1 messenger RNA fell by approximately 25%.
- Only 15 treated participants contributed to the Month 15 analysis, leaving Phase 2/3 FALCON-HD as the decisive efficacy test.
Data Snapshot
| Category | Result |
|---|---|
| Candidate | SKY-0515 |
| Developer | Skyhawk Therapeutics |
| Indication | Huntington’s disease |
| Modality | Once-daily oral RNA-splicing modifier |
| Month 15 population | 15 treated participants |
| cUHDRS change | +0.94 with SKY-0515 vs. −0.65 with external control |
| Treatment difference | +1.59 points |
| Statistical result | 95% CI: 1.09–2.09; p<0.001 |
| Biomarker activity at 9 mg | More than 60% mHTT reduction; approximately 25% PMS1 mRNA reduction |
| Next study | Phase 2/3 FALCON-HD |
The results support sustained target engagement and an encouraging clinical signal, but they do not establish that SKY-0515 slows Huntington’s disease progression.
What Happened
Skyhawk Therapeutics reported the final 15-month results from its Phase 1/2 study of SKY-0515, an investigational oral treatment for Huntington’s disease.
The mean change in the Composite Unified Huntington’s Disease Rating Scale, or cUHDRS, was +0.94 points among SKY-0515-treated participants and −0.65 points in an overlap-weighted external natural-history control. The resulting 1.59-point difference favored SKY-0515, with a 95% confidence interval of 1.09 to 2.09 and a reported p-value below 0.001.
Differences also favored SKY-0515 across all four cUHDRS components, covering daily function, movement, processing speed and reading speed. The company reported no treatment-related serious adverse events through 15 months.
At 9 mg, average mutant huntingtin protein reduction remained above 60%, while PMS1 messenger RNA declined by approximately 25%. (Skyhawk 15-month Phase 1/2 results)
Why It Matters
SKY-0515 is designed to modify RNA splicing and reduce the production of full-length huntingtin. It also lowers PMS1 messenger RNA, potentially affecting a DNA-repair pathway associated with somatic CAG-repeat expansion.
This dual activity differentiates SKY-0515 from programs focused only on huntingtin lowering. One pathway targets production of the disease-causing protein, while the second may influence the continuing expansion of the underlying CAG repeat.
Science Explained
[How SKY-0515 Uses RNA Splicing to Lower HTT and PMS1]
Want to understand the biology behind the readout? Read my science analysis of how SKY-0515 uses RNA-splicing modification to lower full-length huntingtin and PMS1.
The second mechanism remains clinically unproven. SKY-0515 has reduced PMS1 messenger RNA in treated patients, but it has not yet demonstrated slower somatic CAG expansion in the human brain.
The clinical comparison also requires caution. The study was placebo-controlled for its first 12 weeks, but all participants received active treatment during the subsequent extension. The Month 15 analysis therefore compared 15 treated participants with an external natural-history control rather than a concurrent placebo group.
The European Huntington Association described the findings as promising while emphasizing the small, early-stage nature of the study. (European Huntington Association assessment)
BP View
SKY-0515’s biomarker data are the clearest part of the readout. Sustained mutant huntingtin lowering confirms activity against the core disease protein, while PMS1 reduction provides a biologically differentiated second mechanism.
The 1.59-point cUHDRS advantage is encouraging because the signal extended across functional, motor and cognitive measures. However, statistical significance against an external control cannot eliminate the uncertainty created by the small treated population and the absence of a concurrent Month 15 placebo group.
The decisive question is whether SKY-0515 can reproduce this signal in a large randomized study. FALCON-HD includes a completed 144-participant study in Australia and New Zealand, while its worldwide study plans to enroll approximately 600 participants.
A placebo-controlled benefit on motor, cognitive and functional decline would support the dual-target strategy. Until then, the Phase 1/2 results justify further development but do not prove that SKY-0515 modifies Huntington’s disease progression.
Related Post
Read my previous analysis of BioNTech’s Gotistobart Posts 18.5-Month Median Survival in Squamous NSCLC.
About Biopharma Perspective
Biopharma Perspective provides independent analysis of biopharma clinical data, regulatory decisions and competitive strategy, separating what the evidence establishes from what still requires confirmation.
Leave a Reply